ALSO NOTED: Strong euro hitting Merck KGaA's revenue; U.S. sales boost Lupin's Q3 profits;

> German pharma Merck KGaA says a strong euro will depress its year-end sales; it reported a 74.9 percent drop in third-quarter profits on a one-time charge from its acquisition of Serono. Report

> Strong U.S. sales boosted Indian drug maker Lupin in the third quarter, lifting profits by 46 percent to $19 million; sales grew by 35 percent. Report

> Dr. Reddy's Laboratories grew revenues by 20 percent this quarter, but profits fell slightly to $67 million. Release

> Indian pharma Wockhardt did end up acquiring U.S.-based Morton Grove Pharmaceuticals as expected--but at $38 million, the price was lower than rumored. Report

> India's Dabur Pharma inked a deal with Spain-based Combino Pharm to sell generic cancer drugs in that country. Report

> With Biogen Idec on the market, reporters are delving into the possibilities for the company and the potential fallout in the Boston biotech cluster that the company calls home. Report

And Finally... Apparently, the White House didn't like what its CDC chief was planning to tell Congress about global warming's effect on health. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.